ES2920288T3 - Procedimientos para la detección de melanoma - Google Patents

Procedimientos para la detección de melanoma Download PDF

Info

Publication number
ES2920288T3
ES2920288T3 ES18731615T ES18731615T ES2920288T3 ES 2920288 T3 ES2920288 T3 ES 2920288T3 ES 18731615 T ES18731615 T ES 18731615T ES 18731615 T ES18731615 T ES 18731615T ES 2920288 T3 ES2920288 T3 ES 2920288T3
Authority
ES
Spain
Prior art keywords
expression level
hla
cflar
melanoma
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18731615T
Other languages
English (en)
Spanish (es)
Inventor
Irvin Modlin
Mark Kidd
Ignat Drozdov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Liquid Biopsy Research LLC
Original Assignee
Liquid Biopsy Research LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liquid Biopsy Research LLC filed Critical Liquid Biopsy Research LLC
Application granted granted Critical
Publication of ES2920288T3 publication Critical patent/ES2920288T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/107—Nucleic acid detection characterized by the use of physical, structural and functional properties fluorescence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
ES18731615T 2017-05-25 2018-05-21 Procedimientos para la detección de melanoma Active ES2920288T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762511058P 2017-05-25 2017-05-25
PCT/US2018/033658 WO2018217627A1 (en) 2017-05-25 2018-05-21 Methods for melanoma detection

Publications (1)

Publication Number Publication Date
ES2920288T3 true ES2920288T3 (es) 2022-08-02

Family

ID=62620988

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18731615T Active ES2920288T3 (es) 2017-05-25 2018-05-21 Procedimientos para la detección de melanoma

Country Status (13)

Country Link
US (3) US20180340934A1 (cg-RX-API-DMAC7.html)
EP (1) EP3631017B1 (cg-RX-API-DMAC7.html)
JP (1) JP7227964B2 (cg-RX-API-DMAC7.html)
KR (1) KR102763004B1 (cg-RX-API-DMAC7.html)
CN (1) CN111315897B (cg-RX-API-DMAC7.html)
AU (1) AU2018273844B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019024481A2 (cg-RX-API-DMAC7.html)
DK (1) DK3631017T3 (cg-RX-API-DMAC7.html)
ES (1) ES2920288T3 (cg-RX-API-DMAC7.html)
IL (1) IL270787B2 (cg-RX-API-DMAC7.html)
MX (1) MX2019014026A (cg-RX-API-DMAC7.html)
PL (1) PL3631017T3 (cg-RX-API-DMAC7.html)
WO (1) WO2018217627A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019014026A (es) 2017-05-25 2020-08-03 Liquid Biopsy Res Llc Metodos para la deteccion de melanoma.
EP4041886A1 (en) 2019-10-10 2022-08-17 Liquid Biopsy Research LLC Compositions, methods and kits for biological sample and rna stabilization

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006203830A1 (en) * 2005-01-07 2006-07-13 The Johins Hopkins University Biomarkers for melanoma
WO2008031041A2 (en) * 2006-09-07 2008-03-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
NZ576428A (en) * 2006-11-03 2012-04-27 Baylor Res Inst Diagnosis of metastatic melanoma and monitoring indicators of immunosuppression through blood leukocyte microarray analysis
EP2092075A2 (en) 2006-11-06 2009-08-26 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring and treatment of melanoma
US20110070582A1 (en) 2008-11-03 2011-03-24 Source Precision Medicine, Inc. d/b/d Source MDX Gene Expression Profiling for Predicting the Response to Immunotherapy and/or the Survivability of Melanoma Subjects
CN102667484A (zh) * 2009-10-13 2012-09-12 约翰·霍普金斯大学 识别黑素瘤肿瘤细胞的生物标记
WO2012031008A2 (en) 2010-08-31 2012-03-08 The General Hospital Corporation Cancer-related biological materials in microvesicles
WO2014008270A1 (en) * 2012-07-03 2014-01-09 Ratiopharm Gmbh Solid state form of vemurafenib choline salt
US10407730B2 (en) * 2014-09-15 2019-09-10 Clifton Life Sciences LLC Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm
MX2019014026A (es) 2017-05-25 2020-08-03 Liquid Biopsy Res Llc Metodos para la deteccion de melanoma.

Also Published As

Publication number Publication date
EP3631017A1 (en) 2020-04-08
JP7227964B2 (ja) 2023-02-22
DK3631017T3 (da) 2022-06-20
US20260202409A1 (en) 2026-07-16
IL270787B1 (en) 2023-04-01
PL3631017T3 (pl) 2022-09-26
CN111315897A (zh) 2020-06-19
BR112019024481A2 (pt) 2020-07-14
WO2018217627A1 (en) 2018-11-29
US20180340934A1 (en) 2018-11-29
CA3064732A1 (en) 2018-11-29
IL270787B2 (en) 2023-08-01
IL270787A (en) 2020-01-30
KR20200030034A (ko) 2020-03-19
AU2018273844B2 (en) 2024-11-14
MX2019014026A (es) 2020-08-03
CN111315897B (zh) 2024-10-22
US20230022236A1 (en) 2023-01-26
KR102763004B1 (ko) 2025-02-04
US12399179B2 (en) 2025-08-26
JP2020524524A (ja) 2020-08-20
AU2018273844A1 (en) 2019-12-19
EP3631017B1 (en) 2022-03-23

Similar Documents

Publication Publication Date Title
JP7186700B2 (ja) 腫瘍抑制foxo活性を酸化ストレスから区別する方法
Kim et al. Detection of plasma BRAFV600E mutation is associated with lung metastasis in papillary thyroid carcinomas
ES3013599T3 (en) Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm
ES2893469T3 (es) Puntuaciones de riesgo basadas en la expresión de la variante 7 de la fosfodiesterasa 4D humana
ES2742840T3 (es) Biomarcadores de micro-ARN para identificar el riesgo y/o diagnosticar tumor pulmonar
US11993816B2 (en) Circulating microRNA as biomarkers for endometriosis
ES3064298T3 (en) Methods of diagnosing and treating patients with cutaneous squamous cell carcinoma
US20180230545A1 (en) Method for the prediction of progression of bladder cancer
JP2024523848A (ja) 癌検出方法、キットおよびシステム
CN107614696A (zh) 基因表现图谱以及将其应用于乳癌医疗之方法
Wang et al. Identification of a 5-gene signature for clinical and prognostic prediction in gastric cancer patients upon microarray data
Baba et al. PRAME expression as a potential biomarker for hematogenous recurrence of esophageal squamous cell carcinoma
ES2916450T3 (es) Método para la detección de discrasia de células plasmáticas
Usmani et al. MiR-16: A novel hereditary marker in breast cancer and their offspring
Wu et al. Long non-coding RNA Loc344887 is a potential prognostic biomarker in non-small cell lung cancer
EP3631017B1 (en) Methods for melanoma detection
JP2026510430A (ja) がん診断モデルを開発する方法及びがん検出方法の開発におけるその使用
US12371749B2 (en) Molecular pathogenesis of microcarcinoma of the thyroid
CN112813167B (zh) 标志物linc01977及其应用
WO2013132001A1 (en) Prognostic biomarkers for survival after treatment of a cancer disease with radiotherapy and/or chemotherapy
HK40017741A (en) Methods for melanoma detection
HK40017741B (en) Methods for melanoma detection
US20250354219A1 (en) Methods for neuroendocrine cancer detection in saliva
Sutanto Deregulated Expression of SPARCL1, EDIL3 and HEY2 in Primary Colorectal Carcinoma and Corresponding Liver Metastasis
Shahat et al. Evaluation of miR-146a Urinary Level as a Marker for Recurrence of Superficial Bladder Cancer after Transurethral Resection of Bladder Tumor (TUR-BT)